COMP360 psilocybin treatment in TRD
COMP360 psilocybin treatment in TRD is Compass Pathways’ phase 2b randomised controlled study of investigational psilocybin treatment for treatment-resistant depression. The published results report outcomes from a 12-week period after a single 25mg dose combined with psychological support.
Course Overview
COMP360 psilocybin treatment in TRD presents results from Compass Pathways’ phase 2b randomised controlled trial of investigational psilocybin treatment for treatment-resistant depression. The study enrolled 233 patients across 22 sites in 10 countries in Europe and North America and assessed three doses of COMP360 psilocybin: 1mg, 10mg, and 25mg. The reported results, published in the New England Journal of Medicine, focus on safety and efficacy findings. According to the source, a single 25mg dose in combination with psychological support was associated with a statistically significant reduction in depressive symptoms after three weeks, with a response that lasted for up to 12 weeks. This page is most relevant to readers interested in clinical research on psilocybin, treatment-resistant depression, and the role of psychological support alongside dosing.
Who is this for?
Readers interested in clinical research on psilocybin treatment for treatment-resistant depression, including researchers, clinicians, and other professionals following psychedelic medicine studies.
About the Provider
COMPASS Pathways is a UK-listed biopharmaceutical company developing COMP360 synthetic psilocybin therapy for treatment-resistant depression, with two successful Phase 3 trials making it the leading candidate for the first regulatory approval of a classic psychedelic medicine.
View COMPASS Pathways profileCourse Details
- PriceFree
- Lifecycle statusNo New Dates
- SkillsPsilocybin TherapyUnderstanding clinical trial designInterpreting psilocybin treatment researchReviewing safety and efficacy outcomesAnalyzing treatment-resistant depression studies
- Categories
You will be redirected to the provider's website
Related Courses
View all coursesApprenticeship Retreat Immersion Training: 8 Days of Immersive, Guided Apprenticeship New Eden, Netherlands | April 26 – May 3 ❘ August 2 – 6
An 8-day immersive apprenticeship retreat in the Netherlands focused on ethical psychedelic facilitation and group space-holding. Participants observe, support, and reflect within a clinically informed, somatically intelligent training structure.
Automated status check: No valid upcoming cohort date found on the source page (checked 2026-04-12).
Are You Ready for This? The Hidden Curriculum of Psilocybin Training
This article explores the hidden curriculum of psilocybin facilitation: the emotional, relational, and internal skills that training programs often do not fully cover. It frames readiness as a practice of presence, listening, and trust rather than a checklist.
Automated status check: No valid upcoming cohort date found on the source page (checked 2026-04-12).
Berkeley Psychedelic Facilitation Certificate Program (2022 – 2025)
A nine-month professional certificate from UC Berkeley’s Center for the Science of Psychedelics, designed for advanced professionals preparing to support psychedelic care. The program included interdisciplinary instruction, in-person modules, online small-group meetings, and an optional practicum for some licensure pat
Automated status check: No valid upcoming cohort date found on the source page (checked 2026-04-12).